CAI國際 CAI 深 滬
等待開盤 07-06 09:30:00 美东时间
18.30
-0.450
-2.40%
華盛通- 最 高19.675
- 今 開19.01
- 成交量 292.63万股
- 最 低 18.14
- 昨 收 18.75
- 總市值 51.73亿
- 52周最高 42.50
- 市盈率 靜 --
- 換手率 1.04%
- 52周最低 14.19
- 委 比 -5.53%
- 總股本 2.83亿
- 歷史最高 42.50
- 量 比 0.64
- 振 幅 8.19%
- 歷史最低 14.19
- 每 手 1
- 風險率 6.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BTIG Reiterates Buy on Caris Life Sciences, Maintains $32 Price Target
BTIG analyst Mark Massaro reiterates Caris Life Sciences (NASDAQ:CAI) with a Buy and maintains $32 price target.
07-02 18:23
Caris Life Sciences Announces Dual Listing on NYSE Texas
IRVING, Texas, June 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced ...
06-16 20:30
Caris Life Sciences Announces $100M Buyback Plan
Caris Life Sciences® (Nasdaq: CAI) ("Caris" or the "Company"), a leading next-generation AI TechBio company and precision medicine pioneer, today announced that its Board of Directors has authorized a share
06-08 20:35
Caris Life Sciences Announces Share Repurchase Program
IRVING, Texas, June 8, 2026 /PRNewswire/ -- Caris Life Sciences® (Nasdaq: CAI) ("Caris" or the "Company"), a leading next-generation AI TechBio company and precision medicine pioneer, today ...
06-08 20:30
Stock Market Today: Nasdaq 100 Slips As Broadcom Plunges, Bitcoin Hits 4-Month Lows
A selloff in high-flying chipmakers split Wall Street on Thursday, with Broadcom Inc. (NASDAQ:AVGO)‘s disappointing AI-revenue forecast testing the artificial-intelli
06-05 01:09
Wolfe Research Assumes Caris Life Sciences at Peer Perform
Wolfe Research analyst Mike Polark assumes Caris Life Sciences (NASDAQ:CAI) with a Peer Perform rating.
06-02 20:16
Caris Life Sciences Announces Publication Of A Caris‑Led Study In The Oncologist The Shows Its Lookback Program's Ability To Identify Previously-Profiled Patients Who Become Eligible For Newly Approved Targeted Therapies
Molecular profiling reports from most labs are static, reflecting clinical knowledge only at the time of testing. As new biomarker–drug associations and therapeutic indications emerge, patients with previously identified
05-15 20:36
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
BTIG Maintains Buy on Caris Life Sciences, Lowers Price Target to $32
BTIG analyst Mark Massaro maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and lowers the price target from $38 to $32.
05-08 18:36
